Loading...
XNASSSKN
Market cap12mUSD
Dec 27, Last price  
2.97USD
1D
3.48%
1Q
0.63%
Jan 2017
35.00%
IPO
-95.29%
Name

STRATA Skin Sciences Inc

Chart & Performance

D1W1MN
XNAS:SSKN chart
P/E
—
P/S
0.37
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
5.15%
Rev. gr., 5y
2.24%
Revenues
33m
-7.75%
00000000278,461536,000915,00018,495,00031,757,00031,449,00029,855,00031,586,00023,090,00029,977,00036,161,00033,357,999
Net income
-11m
L+95.17%
-3,619,146-6,726,347-10,591,477-11,937,444-17,605,031-18,452,844-19,922,515-20,384,715-22,673,000-25,948,000-16,032,000-27,909,000-3,335,000-21,514,000-4,033,000-3,790,000-4,412,000-2,706,000-5,549,000-10,830,000
CFO
-519k
L-53.16%
-3,064,613-5,865,133-10,141,345-11,048,937-16,204,517-17,302,714-18,820,489-17,457,861-19,223,676-19,413,000-17,709,000-6,585,000322,0004,140,0002,896,0002,229,0002,096,0001,508,000-1,108,000-519,000
Earnings
Mar 25, 2025

Profile

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
URL
http://www.strataskinsciences.com/
IPO date
Oct 28, 2005
Employees
114
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
33,358
-7.75%
36,161
20.63%
29,977
29.83%
Cost of revenue
39,678
40,810
34,379
Unusual Expense (Income)
NOPBT
(6,320)
(4,649)
(4,402)
NOPBT Margin
Operating Taxes
(92)
63
34
Tax Rate
NOPAT
(6,228)
(4,712)
(4,436)
Net income
(10,830)
95.17%
(5,549)
105.06%
(2,706)
-38.67%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
704
355
318
Long-term debt
15,870
9,051
8,421
Deferred revenue
552
314
400
Other long-term liabilities
1,135
8,309
Net debt
9,790
3,972
(3,847)
Cash flow
Cash from operating activities
(519)
(1,108)
1,508
CAPEX
(5,019)
(3,552)
(3,653)
Cash from investing activities
(5,019)
(4,183)
(7,126)
Cash from financing activities
6,861
(500)
92
FCF
(11,764)
(5,664)
(5,440)
Balance
Cash
6,784
5,434
12,586
Long term investments
Excess cash
5,116
3,626
11,087
Stockholders' equity
(238,023)
(227,193)
(221,645)
Invested Capital
268,383
262,102
251,791
ROIC
ROCE
EV
Common stock shares outstanding
3,492
3,471
3,405
Price
0.55
-30.38%
0.79
-46.07%
1.47
-2.33%
Market cap
1,921
-29.96%
2,743
-45.02%
4,988
-1.05%
EV
11,711
6,715
1,141
EBITDA
(418)
1,039
(316)
EV/EBITDA
6.46
Interest
1,640
926
314
Interest/NOPBT